CRISPR Therapeutics
CRSP
CRSP
480 hedge funds and large institutions have $4.1B invested in CRISPR Therapeutics in 2024 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 158 increasing their positions, 137 reducing their positions, and 56 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
480
Holders Change
+11
Holders Change %
+2.35%
% of All Funds
6.96%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
74
Increased
158
Reduced
137
Closed
56
Calls
$256M
Puts
$212M
Net Calls
+$44.1M
Net Calls Change
+$41M
Top Buyers
Top Sellers
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$61.8M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$46.5M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$25.8M |
| 4 |
Jane Street
New York
|
-$20.4M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$19.1M |
